Introduction
============

As a member of a subfamily chromosome-associated proteins known as SMCs (Structural Maintenance of Chromosomes), which are highly conserved from bacteria to humans, SMC1 is a core component of the cohesin complex that is required for sister chromatid cohesion [@B1]-[@B3]. In addition, SMC1 is involved in a variety of cellular functions, including cell survival [@B4], chromosome dynamics [@B5]-[@B7], cell cycle regulation [@B8], [@B9] and DNA damage repair [@B10]-[@B12]. Importantly, SMC1-mediated chromosome structure stability and DNA damage repair are considered as important mechanisms for the maintenance of genome integrity. Although there is increasing evidence that SMC1 is closely associated with various cancer types, current knowledge about its role in tumorigenesis remains limited.

In this review, we summarize the current knowledge on SMC1 in cell cycle regulation, genomic stability and its mutations in various cancers, and discuss the potential role of SMC1 serving as a biomarker in clinical cancer diagnosis.

Overview of SMC1
================

The SMC proteins were initially identified through genetic studies of chromosome segregation in Saccharomyces cerevisiae [@B13]. Smc1p, characterized as the founding member of SMC1 family proteins by frequent minichromosome nondisjunction in mutations [@B14], was later shown to be essential for viability and maintaining cohesion between sister chromatid [@B13].

The SMC1 protein contains a N-terminus ATP binding domain and a C-terminus ATP hydrolysis domain, which are separated by two long coiled-coils of 200-450 residues and a central globular hinge region [@B15], [@B16]. In an antiparallel orientation, these two domains form a functional ATPase [@B17]-[@B19], which could regulate DNA binding and tethering [@B20], [@B21]. Furthermore, deacetylation of SMC1 and SMC3 dimers promotes dissociation of the coiled- coil arms [@B22].

Classically, SMC1 and SMC3 are believed to form a heterodimer in an antiparallel mode as the core of cohesin complex, which is required for sister chromatid cohesion during replication [@B1], [@B2], [@B23], [@B24], and is also involved in recombination as part of the RC-1 complex with DNA polymerase ε and ligase Ⅲ [@B3], [@B25], [@B26]. In humans, two different isoforms of SMC1, SMC1A and SMC1B have been discovered. SMC1A is the core subunit of the mitotic cohesin complex, which is composed of SMC1A, SMC3, Rad21 [@B27]-[@B30] and SA1 or SA2 [@B3], [@B28], [@B31], [@B32]. SMC1B is currently thought as a meiotic specific subunit of cohesin complex, called SMC1B, REC8 or STAG3 respectively [@B33], which plays a key role in sister chromatid pairing and preventing telomere shortening [@B34]-[@B36]. Recent studies showed that SMC1B is also expressed in somatic mammalian cells as a member of a mitotic cohesin complex preserving genome stability in response to irradiation [@B37].

SMC1 in chromosome dynamics and cell cycle
==========================================

Under normal conditions, SMC1 as part of cohesin, is recruited to chromatin in G1 phase with sister chromatid cohesion taking place in S phase, and holds sister chromatid together until accurate chromosome segregation in M phase during the cell cycle [@B38]-[@B41]. In addition, SMC1 was also found to be present at centrioles of a centrosome at G~0~/G~1~ stage to function as a centrosomal protein [@B42]. During mitosis, SMC1 was observed at the spindle poles [@B43], [@B44] and the active centromere on dicentric chromosomes in concomitant with functional kinetochore [@B45]. It was reported that the injection of an antibody specific for hSMC1 into human mitotic cells blocked the progression of metaphase and led to disorganization of the metaphase plate [@B46]. Cytoplasmic mislocation of SMC3 and degradation of SMC1 and RAD21 can also be induced by SMC1 knockdown [@B47]. These results demonstrate that SMC1 is tightly associated with cell cycle progression and may function as a unique regulator.

SMC1 participates in DNA damage repair and genomic stability maintenance
========================================================================

In addition to the canonical role in sister chromatid cohesion, SMC1 is also a core component of the tetrameric complex cohesin, which coordinates the HR (Homologous Recombination) pathways for DNA DSB (Double Strand Breaks) repair [@B48], [@B49]. SMC1 deletion was found to compromise the DSB repair in G~2~-phase cells [@B50], but phosphorylation of SMC1 is actually the final performer of its function. Yazdi and Kim et al. firstly reported that SMC1, which is phosphorylated by ATM in serine 957 and 966, acts as a downstream effector of a separate branch of the S-phase checkpoint pathway, namely the ATM/NBS1/SMC1 pathway in response to IR (Ionization Radiation) [@B51]-[@B53]. This pathway could also be triggered by H/R (Hypoxia and Reoxygenation)-induced DNA damage [@B54]. In this pathway, both NBS1 and BRCA1 were required for the recruitment and maintenance of activated ATM to the site of DSB associated with efficient phosphorylation of SMC1 by ATM [@B52], which could be disrupted by the UBD (Ubiquitin Binding Domains) of RAD18 [@B55]. SMC1 could also be phosphorylated after exposure to UV irradiation or hydroxyurea by ATR as well [@B56]-[@B59]. Furthermore, the absence of SMC1A leads to chromosomal aneuploidy and aberrations at fragile sites in human fibroblast cells [@B57]. Cells expressing phosphorylation mutant of SMC1 show a defective S-phase checkpoint, decreased survival and increased chromosomal aberrations after IR [@B60]. However, phosphorylation of SMC1 dose not alter the IR-induced G~2~/M checkpoint, while having an effect on G~2~ phase accumulation [@B51].

Increasing evidence demonstrates that the fully assembled cohesin is required for phosphorylation of SMC1, in other words, SMC1 is phosphorylated as part of cohesin [@B11], [@B61]. Specifically, SMC1 phosphorylation requires the phosphorylation of NBS1 by ATM, establishing NBS1, whose N- and C- terminus are indispensable for the interaction with SMC1, as an adaptor in the ATM/NBS1/SMC1 pathway [@B51]. NBS1-T278 phosphorylation may be a major site assisting SMC1 phosphorylation upon high dose of DNA damage [@B62]. Meanwhile, absence of NBS1 causes delay of SMC1 phosphorylation [@B63]. As either regulators or cofactors, several other proteins are also uncovered to be involved in regulating the SMC1 pathways for cell cycle checkpoint and DNA damage repair. For example, knocking down MDC1 (Mediator of DNA Damage Checkpoint protein 1) decreases the phosphorylation of SMC1 [@B64] and prevents activation of the intra-S phase and G~2~/M phase cell-cycle checkpoints after exposure to IR. PTIP (Pax2 transactivation domain-interacting protein) upstreams 53BP1-ATM-SMC1 pathway, where SMC1 is phosphorylated at the DNA damage sites, for DNA DSBs repair and activation of the DNA damage-induced intra-S phase checkpoint [@B65] (Figure [1](#F1){ref-type="fig"}).

In addition, SMC1 participates in the maintenance of genomic stability and is required for bipolar mitosis in human cells [@B66]. ATM anchored at spindle pole or a related kinase presumably phosphorylates Ser-957 and Ser-966 of SMC1, which in turn stimulates its binding to the microtubule-associated Rae1 [@B44]. Overexpression of wild-type SMC1, but not the mutant SMC1-S957A, SMC1-S966A or SMC1-DBA (Double S957A and S966A) that fails to interact with Rae1, resulted in more multipolar and less bipolar spindle phenotypes [@B44], [@B67].

Mouse models with SMC1A targeted showed a series of phenotypic characteristics in development. MGI (Mouse Genome Informatics) database provided the valuable information in targeted mutation mouse of SMC1A^S957AS966A^ (SMC1A^tm1Mbk^, tm1: targeted mutation 1; Mbk: Michael B Kastan). The phenotype of SMC1A^tm1Mbk^ mouse were premature death, abnormal hematopoietic and immune system.

Nevertheless, it is generally believed that SMC1B is a meiotic specific member of cohesin. The current study showed that SMC1B was also expressed in somatic mammalian cells. The cell cycle progression of SMC1B-slienced cells was alike to the control cells. SMC1B was shown to safeguard genome stability by allowing DSB repair following IR whereas its depletion had no effect on chromosome cohesion [@B37]. Interestingly, the phenotypes of SMC1B-deficient mice were different. Initial observations of mice deficient in SMC1B were conducted by Revenkova et al. They found that SMC1B^-/-^ mice were viable and showed normal mating behavior. However, the weight of SMC1B^-/-^ mice was only half of heterozygous or wild-type littermates. Both males and females were infertile in SMC1B^-/-^ mice. Males exhibited meiotic arrest in pachytene. Female meiosis progressed through meiosis I until metaphase II, but premature loss of sister chromatid cohesion resulting in massive aneuploidy [@B7]. Furthermore, SMC1B^-/-^ female mice showed shifting of chiasmata placement and missing of cohesion with age [@B68]. In summary, SMC1-mediated DNA damage repair and genomic stability maintenance are prevalent under conditions of IR or UV radiation, and this process can be modulated by its phosphorylation. Thus, it is quite clear that alteration of expression and phosphorylation mutations could cause dysfunction of cell cycle checkpoint and failure of DNA damage repair which lead to genomic instability and tumorigenesis.

SMC1 and its mutations in tumorigenesis
=======================================

The role of SMC1 in cancer
--------------------------

SMC1, whose abnormality has been enumerated as enabling characteristics of cancer, properly appears to contribute to chromosome stability, DNA damage checkpoint and repair [@B69]. Thus it is plausible to suggest that the expression of SMC1 and its mutations are able to influence cells from being normal to malignant. SMC1 has been previously found to be involved in the pathogenesis of several types of tumors associated with up-regulation of its expression. SMC1A is over expressed in colorectal cancer tissues and its expression level is correlated with poor prognosis for late stage patients. Increased expression of SMC1A is also profoundly associated with distant metastasis and advanced TNM (Tumor Lymph Nodes Metastasis) stage of disease. In contrast, SMC1A knockdown resulted in a significant inhibition of cell proliferation, colony formation, cell cycle progression and up-regulation of apoptosis in colorectal cancer cells, as well as prevention of colon tumorigenesis in nude mouse models [@B70]. Accordingly, SMC1A deficiency results in inhibition of cell proliferation, increased apoptosis and enhanced chemosensitivity to oxaliplatin [@B71]. Being consistent with its role in tumorigenesis, SMC1A was found to be highly expressed in TNBC (Triple-Negative Breast Cancer) cell lines, localizing in the nucleus, cytoplasm and plasma membrane along with SMC3 [@B72]. Overexpression of SMC1A also increases EMT (Epithelial-Mesenchymal Transition) in TNBC through the induction of Brachyury, a protein encoded by the T gene in humans, which is a transcription factor within the T-box complex of genes [@B73]. Moreover, SMC1A is highly expressed in human glioma tissues versus surrounding normal tissues and U25L cells, while knocking down SMC1A expression leads to G~2~/M arrest, decreased cell growth and cyclin B1 expression [@B74], [@B75]. SMC1B expression is closely related to increased invasiveness and aggressiveness of several cancers [@B76]-[@B78]. High SMC1B expression has been shown to be associated with pancreatic cancer [@B76] and the radioresistant H1299 cells than in the radiosensitive H460 cells [@B78].

Conversely, in other types of tumors, such as AML (Acute Myelocytic Leukemia), patients, with a moderate to high SMC1A protein expression, show a significantly improved cancer-free survival as well as overall survival, which suggests that low expression of SMC1A protein could have a poor prognosis [@B79]. However, in patients with early-stage head and neck cancer, decreased SMC1B expression leads to potentially increased genome instability and greater cancer progression risk, which could account for the risk of SPT (Second Primary Tumor) and/or recurrence [@B80].

In conclusion, SMC1 expression is dysregulated in various human cancers associated with prognostic indicators. Aberrant expression of SMC1 is confirmed by analysis of SMC1 gene expression data setting at Oncomine (Figure [2](#F2){ref-type="fig"}).

SMC1 mutations are prevalent in human cancers
---------------------------------------------

SMC1 mutations have been identified in human cancers. Being different from other cohesin mutations that were heterozygous in nature, SMC1A gene locates on chromosome X as a single allele, thereby its mutation cannot be heterozygous. The first somatic mutation of SMC1A in human tumors was reported in 2008 wherein Barber et al. identified somatic mutations in 4 out of 132 colorectal cancers (F396L/F, R434W, I560I/M and V1186I/V) [@B81]. Later, Cucco et al. screened 11 somatic mutations in early colorectal adenomas but only one mutation in colorectal carcinomas. SMC1A mutations decrease almost 5 fold during colon cancer development in early adenomas than in colorectal cancers. Mechanistically, overexpression of the mutations identified in early adenomas can cause chromosomal instability and aneuploidy [@B82].

In addition to colorectal cancer, there has been increasing evidences for SMC1 mutations in AML. In 2013, the Cancer Genome Atlas reported cohesin mutations in 26 of 200 de novo AMLs (13%) including 7 with SMC1A mutations (6/7 missense) [@B83]. Subsequently, the mutation frequency of SMC1A among 389 AML patients was evaluated by Thol et al., and found 2 male patients with 2 missense mutations in SMC1A (A078V, R816S) were identified [@B84]. Moreover, Kon et al. detected 4 different SMC1A mutations among 610 myeloid neoplasm samples (K190T, R586W, M689V and R807H). Interestingly, hemimethylation of the SMC1A promoter was found in two female cases. However, the expression of SMC1A was not significant different in 17 myeloid leukemia cell lines with or without known cohesin mutations. However, in cell lines (Kasumi-1, KG-1, P31FUJ, MOLM-7 and MOLM-13) with mutated or reduced expression of cohesin components, SMC1A is significantly reduced in the chromatin-bound fractions [@B85]. There is some evidence t that cohesin gene mutations may also act as an initiation of a subset of AMLs. Welch et al. indentified 2 SMC1A recurrent mutations in AML through whole genome sequencing [@B86]. In addition, a study by Yoshida et al. evaluated 2 SMC1A somatic mutations in DS-AMKL (Down Syndrome-related Acute Megakaryoblastic Leukemia) (R196H, E418_splice) [@B87]. Similarly, Huether et al. indentified 4 mutations of SMC1A in pediatric CBF AML (Core Binding Factor Acute Myeloid Leukemia) (\*insR131, R92G, G1131R, R196C) [@B88].

In several other tumor types, mutations of SMC1A have been detected as well. Firstly, it was reported that SMC1A mutations were found in Ewing sarcoma, known as a very rare type of malignant tumor whose cancer cells were found in the pediatric bone and soft tissue. In the United States, about 200 children and young adults suffer from it annually and it shows a mild preference for males [@B89]. Substantial effort has been made to look for genes that are mutated in Ewing sarcoma tumors. Crompton et al. identified SMC1A mutations (1%, E141K) in addition to STAG2 mutations commonly in Ewing sarcoma [@B90]. In another large scale sequencing study, Guo et al. found occasional somatic mutations in SMC1A (3%) [@B91]. Then, 1 SMC1A mutation in pediatric Ependymoma (T182_F184del) was identified [@B88]. Finally, Balbas Martinez et al. identified 3% frequent somatic mutations in SMC1B in bladder cancer by exome sequencing (413, 188) [@B92]. Interestingly, transposon insertional mutagenesis in SMC1B mice were found to be more susceptible to intestinal tumor [@B93].

Taken together, these studies indicate that SMC1 mutation could be a significant event in several tumor types, albeit with a low mutation rate (1%-4%). Given that phosphorylation of SMC1 plays an important role in the maintenance of genome stability [@B66], mutations in the serine, threonine or tyrosine residues of SMC1 that can be phosphorylated have also been extensively studied, which were summarized in SMC1A and SMC1B data sets at cBioPortal (Figure [3](#F3){ref-type="fig"}).

Conclusion
==========

As a core part of the cohesin complex, SMC1 is required for sister chromatid cohesion and maintenance of the genome integrity. Moreover, it can be activated to facilitate genome amplification under conditions of viral infection [@B8], [@B94], [@B95]. These characteristics make SMC1 a pivotal molecular linked to human tumorigenesis and ontogenesis [@B96].

We can surmise that SMC1 expression could be regulated by other unknown proteins or factors and its wax or wane interferes with genome stability which finally triggers the onset of cancer, from evidence that the expression quantity change of SMC1A and SMC1B was found to be existed widely in human cancers. Nonetheless, it is still elusive about pathways taken by SMC1 per se to complicate the maintenance of genome integrity or induced DNA damage checkpoint/repair through intricate protein interactions. Likewise, SMC1A mutations may lead to chromosomal instability by two different ways. On one hand, SMC1A mutations are directly associated with the classical functions of cohesion. These mutations might result in chromosome imbalance with chromosome loss or gain through influencing correct chromosome segregation. On the other hand, cohesion is recently found to be implicated in the regulation of gene expression. SMC1A mutations could contribute to tumorigenesis via regulating the expression of proto-oncogenes or tumor suppressor genes, given that cohesin is recently found to be implicated in the regulation of gene expression. Furthermore, the SMC1 activity can be regulated by phosphorylation and acetylation.

Here, we summarized the expression and phosphorylation mutations for the human SMC1 gene in cancers. In particular, we focus on the functional effects of SMC1 mutations as well as crucial questions that need to be addressed in future in order to provide a promising target for the treatment of malignant tumors.
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![Schematic representation of the SMC1 participating in DNA damage repair signaling pathway. After DSB induced, BRCA1, cohesin (SMC1, SMC3 and RAD21) and MRN complex (MRE11, Rad50 and NBS1) are recruited to the damage site. Intermolecular autophosphorylation of ATM dimmers leads to release of active ATM monomers. Active ATM monomers can phosphorylate substrates such as BRCA1, NBS1 and SMC1. Both BRCA1 and NBS1 are required for the phosphorylation of SMC1, fully assembled as part of cohesin, by activated ATM, thus inducing S phase arrest. PTIP, MDC1 and RAD18 are involved in regulating SMC1 phosphorylation. Green Arrows represent activating events and red perpendicular ends represent inhibitory events.](ijbsv13p1092g001){#F1}

![Data showed SMC1 genes are aberrantly expressed in human cancers compared to their normal tissue. Red represents over-expression, and yellow represents low-expression in tumor versus normal tissue. The volume indicates the percentage of the two different expression forms.](ijbsv13p1092g002){#F2}

![Mutations of serine, threonine and tyrosine of the two isoforms of SMC1, widely existed in human cancers, are exhibited in the form above. These mutations dysfunction the effective phosphorylation of SMC1 proteins, thus interrupting maintenance of genome stability and DSB repair. Asterisk represents nonsense mutation.](ijbsv13p1092g003){#F3}
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